Pharmacyclics Plans Xcytrin NDA Based On New Data Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Overall Phase III results for motexafin in brain metastases failed to meet endpoints but additional analyses found positive results from U.S. trial group.